

Edgar Filing: HEMACARE CORP /CA/ - Form 8-K

HEMACARE CORP /CA/
Form 8-K
April 09, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549

FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934

Date of Report (Date of earliest event reported): April 8, 2003

HEMACARE CORPORATION
(Exact name of registrant as specified in its charter)

CALIFORNIA
(State or other jurisdiction of incorporation)

000-15223
(Commission File No.)

95-3280412
(IRS Employer Identification No.)

21101 Oxnard Street
Woodland Hills, CA 91367
(Address of principal executive offices and Zip Code)

Registrant's telephone number, including area code: (818) 226-1968

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION
AND EXHIBITS

(c) Exhibits

Exhibit Number Description

99.1 Press Release issued by HemaCare Corporation,
dated April 8, 2003

ITEM 9. REGULATION FD DISCLOSURE

Edgar Filing: HEMACARE CORP /CA/ - Form 8-K

The text of a press release dated April 8, 2003, issued by HemaCare Corporation ("HemaCare") regarding the development of a new liquid intravenous gamma globulin (IVIG) manufacturing process is attached as Exhibit 99.1 hereto and is incorporated by reference herein. However, there can be no assurance that HemaCare will be successful in obtaining a U.S. patent for the IVIG manufacturing process or that HemaCare will be able to license this process to commercial fractionators.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 8, 2003

HEMACARE CORPORATION

/s/ Judi Irving

Judi Irving,
Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Description
-----	-----
99.1	Press Release issued by HemaCare Corporation, dated April 8, 2003.